Characteristics of patients with sAML as per front-line treatment (n = 2152)
| Characteristic . | IC . | Non-IC . | HMA . | Clinical trial . | BSC . | P value . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | ||
| Total | 876 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| Age, y | 61 (18-85) | 875 (100) | 72 (24-91) | 325 (100) | 73 (29-88) | 327 (100) | 72 (31-89) | 79 (100) | 77 (23-104) | 542 (100) | <.001* |
| Gender | 870 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| Male | 518 (59) | 199 (61) | 209 (64) | 52 (66) | 305 (56) | .15 | |||||
| Female | 352 (41) | 126 (39) | 119 (36) | 27 (34) | 239 (44) | ||||||
| ECOG | 1 (0-4) | 726 (100) | 1 (0-4) | 256 (100) | 1 (0-4) | 273 (100) | 1 (0-3) | 75 (100) | 2 (0-4) | 433 (100) | <.001* |
| 0 | 252 (34) | 62 (24) | 50 (18) | 26 (35) | 57 (13) | <.001 | |||||
| 1 | 320 (44) | 101 (40) | 134 (49) | 38 (51) | 99 (23) | ||||||
| 2 | 113 (16) | 59 (23) | 70 (26) | 10 (13) | 126 (29) | ||||||
| 3 | 35 (5) | 26 (10) | 17 (6) | 1 (1) | 115 (27) | ||||||
| 4 | 6 (1) | 8 (3) | 2 (1) | 0 (0) | 36 (8) | ||||||
| Type of sAML | 764 (100) | 302 (100) | 258 (100) | 76 (100) | 481 (100) | ||||||
| MDS-AML, MDS/ MPN, and MPN-AML | 429 (56) | 209 (69) | 189 (73) | 55 (72) | 354 (74) | <.001 | |||||
| t-AML | 261 (34) | 68 (23) | 51 (20) | 14 (19) | 83 (17) | ||||||
| Neo-AML | 74 (10) | 25 (8) | 18 (7) | 7 (9) | 44 (9) | ||||||
| FAB subtype | 658 (100) | 252 (100) | 189 (100) | 50 (100) | 341 (100) | ||||||
| M0/M6/M7 | 100 (15) | 37 (15) | 26 (14) | 6 (12) | 59 (17) | <.001 | |||||
| M1/M2 | 233 (35) | 86 (34) | 40 (21) | 18 (36) | 103 (30) | ||||||
| M4/M5 | 196 (30) | 56 (22) | 28 (15) | 11 (22) | 92 (27) | ||||||
| Not available | 129 (20) | 73 (29) | 95 (50) | 15 (30) | 87 (26) | ||||||
| WBC, ×109/L | 6.7 (0.1-289) | 800 (100) | 6.3 (0.4-312) | 296 (100) | 4.3 (0.5-214) | 300 (100) | 4.7 (0.5-158) | 78 (100) | 10.2 (0.2-310) | 484 (100) | <.001* |
| Hemoglobin, g/dL | 9.1 (3.3-17.2) | 730 (100) | 8.8 (4.1-13.9) | 287 (100) | 8.9 (4.8-14.9) | 293 (100) | 9.0 (3.2-14.3) | 76 (100) | 8.9 (3.4-16.4) | 393 (100) | .02* |
| Platelet count, ×109/L | 49 (2-1442) | 731 (100) | 50 (1-1645) | 287 (100) | 59 (3-870) | 294 (100) | 40 (7-350) | 76 (100) | 58 (1-1372) | 396 (100) | .15* |
| BM blasts, % | 50 (0-100) | 676 (100) | 39 (3-100) | 270 (100) | 32 (0-100) | 286 (100) | 34 (16-94) | 74 (100) | 47 (3-100) | 324 (100) | <.001* |
| Creatinine, mg/dL | 0.87 (0.07-7.2) | 613 (100) | 0.99 (0.39-3.63) | 220 (100) | 0.99 (0.47-7) | 185 (100) | 0.96 (0.42-1.84) | 69 (100) | 1.12 (0.25-9.2) | 281 (100) | <.001* |
| ≤1.3 | 534 (87) | 172 (78) | 149 (81) | 59 (86) | 182 (65) | <.001 | |||||
| >1.3 | 79 (13) | 48 (22) | 36 (19) | 10 (14) | 99 (35) | ||||||
| Urea, mg/dL | 32 (4-255) | 547 (100) | 42 (1.9-162) | 205 (100) | 41 (12-195) | 170 (100) | 38 (12-117) | 68 (100) | 47 (10-267) | 246 (100) | <.001* |
| Uric acid, mg/dL | 4.7 (0-14.4) | 540 (100) | 5.6 (0-17.1) | 187 (100) | 5.7 (1.7-13.6) | 158 (100) | 5.3 (0.1-11) | 61 (100) | 6.1 (0.6-21) | 218 (100) | <.001* |
| Bilirubin, mg/dL | 0.6 (0.1-8.1) | 582 (100) | 0.7 (0.1-9.9) | 207 (100) | 0.7 (0.2-5.3) | 172 (100) | 0.7 (0.2-3.9) | 65 (100) | 0.7 (0.2-8.1) | 248 (100) | .01* |
| AST, U/L | 22 (5-213) | 565 (100) | 22 (8-154) | 204 (100) | 20 (7-88) | 163 (100) | 22 (11-99) | 56 (100) | 23 (7-141) | 238 (100) | .18* |
| ALT, U/L | 20 (3-498) | 577 (100) | 19 (2-233) | 206 (100) | 16 (3-91) | 170 (100) | 18 (4-623) | 59 (100) | 19 (3-168) | 247 (100) | .02* |
| AP, U/L | 76 (2-1252) | 533 (100) | 75 (18-812) | 186 (100) | 73 (19-894) | 159 (100) | 75 (42-416) | 55 (100) | 95 (23-3571) | 208 (100) | <.001* |
| Albumin, g/dL | 3.7 (2-5.8) | 508 (100) | 3.7 (2-5.2) | 187 (100) | 3.8 (2.7-5.9) | 143 (100) | 4.1 (2-5) | 61 (100) | 3.4 (1.7-7) | 197 (100) | <.001* |
| ≤3.5 | 212 (42) | 86 (46) | 53 (37) | 18 (30) | 107 (54) | .001 | |||||
| > 3.5 | 296 (58) | 101 (54) | 90 (63) | 43 (70) | 90 (46) | ||||||
| LDH, U/L | 471 (12-9540) | 602 (100) | 437 (57-12 460) | 253 (100) | 385 (61-4266) | 220 (100) | 390 (144-3557) | 63 (100) | 617 (102-13 420) | 302 (100) | <.001* |
| Cytogenetics | 876 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| Normal | 255 (29) | 93 (29) | 107 (33) | 29 (37) | 90 (17) | <.001 | |||||
| Abnormal | 422 (48) | 161 (50) | 152 (46) | 41 (52) | 192 (35) | ||||||
| No metaphases | 76 (9) | 27 (8) | 19 (6) | 2 (3) | 31 (6) | ||||||
| Not available | 123 (14) | 44 (14) | 50 (15) | 7 (9) | 231 (42) | ||||||
| MRC cytogenetic risk | 690 (100) | 256 (100) | 263 (100) | 71 (100) | 277 (100) | ||||||
| Favorable | 40 (6) | 8 (3) | 2 (1) | 0 (0) | 4 (2) | <.001 | |||||
| Intermediate | 386 (56) | 147 (57) | 150 (57) | 46 (65) | 148 (53) | ||||||
| Adverse | 264 (38) | 101 (40) | 111 (42) | 25 (35) | 125 (45) | ||||||
| FLT3-ITD | 467 (100) | 174 (100) | 118 (100) | 70 (100) | 122 (100) | ||||||
| Positive | 54 (12) | 20 (11) | 10 (8) | 10 (14) | 12 (10) | .76 | |||||
| Negative | 413 (88) | 154 (89) | 10108 (92) | 60 (85) | 110 (90) | ||||||
| NPM1 | 427 (100) | 169 (100) | 113 (100) | 67 (100) | 113 (100) | ||||||
| Positive | 85 (20) | 25 (15) | 16 (14) | 8 (12) | 11 (10) | .06 | |||||
| Negative | 342 (80) | 144 (85) | 97 (86) | 59 (88) | 102 (90) | ||||||
| Period | 876 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| 1990-1994 | 33 (4) | 7 (2) | 0 (0) | 0 (0) | 13 (2) | <.001 | |||||
| 1995-1999 | 68 (8) | 2 (1) | 0 (0) | 0 (0) | 28 (5) | ||||||
| 2000-2004 | 92 (11) | 2 (1) | 3 (1) | 0 (0) | 66 (12) | ||||||
| 2005-2009 | 168 (19) | 23 (7) | 51 (16) | 0 (0) | 164 (30) | ||||||
| 2010-2014 | 290 (33) | 171 (53) | 132 (40) | 23 (29) | 192 (35) | ||||||
| 2015-2019 | 225 (26) | 120 (37) | 142 (43) | 56 (71) | 81 (15) | ||||||
| Characteristic . | IC . | Non-IC . | HMA . | Clinical trial . | BSC . | P value . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | Median (range) . | n (%) . | ||
| Total | 876 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| Age, y | 61 (18-85) | 875 (100) | 72 (24-91) | 325 (100) | 73 (29-88) | 327 (100) | 72 (31-89) | 79 (100) | 77 (23-104) | 542 (100) | <.001* |
| Gender | 870 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| Male | 518 (59) | 199 (61) | 209 (64) | 52 (66) | 305 (56) | .15 | |||||
| Female | 352 (41) | 126 (39) | 119 (36) | 27 (34) | 239 (44) | ||||||
| ECOG | 1 (0-4) | 726 (100) | 1 (0-4) | 256 (100) | 1 (0-4) | 273 (100) | 1 (0-3) | 75 (100) | 2 (0-4) | 433 (100) | <.001* |
| 0 | 252 (34) | 62 (24) | 50 (18) | 26 (35) | 57 (13) | <.001 | |||||
| 1 | 320 (44) | 101 (40) | 134 (49) | 38 (51) | 99 (23) | ||||||
| 2 | 113 (16) | 59 (23) | 70 (26) | 10 (13) | 126 (29) | ||||||
| 3 | 35 (5) | 26 (10) | 17 (6) | 1 (1) | 115 (27) | ||||||
| 4 | 6 (1) | 8 (3) | 2 (1) | 0 (0) | 36 (8) | ||||||
| Type of sAML | 764 (100) | 302 (100) | 258 (100) | 76 (100) | 481 (100) | ||||||
| MDS-AML, MDS/ MPN, and MPN-AML | 429 (56) | 209 (69) | 189 (73) | 55 (72) | 354 (74) | <.001 | |||||
| t-AML | 261 (34) | 68 (23) | 51 (20) | 14 (19) | 83 (17) | ||||||
| Neo-AML | 74 (10) | 25 (8) | 18 (7) | 7 (9) | 44 (9) | ||||||
| FAB subtype | 658 (100) | 252 (100) | 189 (100) | 50 (100) | 341 (100) | ||||||
| M0/M6/M7 | 100 (15) | 37 (15) | 26 (14) | 6 (12) | 59 (17) | <.001 | |||||
| M1/M2 | 233 (35) | 86 (34) | 40 (21) | 18 (36) | 103 (30) | ||||||
| M4/M5 | 196 (30) | 56 (22) | 28 (15) | 11 (22) | 92 (27) | ||||||
| Not available | 129 (20) | 73 (29) | 95 (50) | 15 (30) | 87 (26) | ||||||
| WBC, ×109/L | 6.7 (0.1-289) | 800 (100) | 6.3 (0.4-312) | 296 (100) | 4.3 (0.5-214) | 300 (100) | 4.7 (0.5-158) | 78 (100) | 10.2 (0.2-310) | 484 (100) | <.001* |
| Hemoglobin, g/dL | 9.1 (3.3-17.2) | 730 (100) | 8.8 (4.1-13.9) | 287 (100) | 8.9 (4.8-14.9) | 293 (100) | 9.0 (3.2-14.3) | 76 (100) | 8.9 (3.4-16.4) | 393 (100) | .02* |
| Platelet count, ×109/L | 49 (2-1442) | 731 (100) | 50 (1-1645) | 287 (100) | 59 (3-870) | 294 (100) | 40 (7-350) | 76 (100) | 58 (1-1372) | 396 (100) | .15* |
| BM blasts, % | 50 (0-100) | 676 (100) | 39 (3-100) | 270 (100) | 32 (0-100) | 286 (100) | 34 (16-94) | 74 (100) | 47 (3-100) | 324 (100) | <.001* |
| Creatinine, mg/dL | 0.87 (0.07-7.2) | 613 (100) | 0.99 (0.39-3.63) | 220 (100) | 0.99 (0.47-7) | 185 (100) | 0.96 (0.42-1.84) | 69 (100) | 1.12 (0.25-9.2) | 281 (100) | <.001* |
| ≤1.3 | 534 (87) | 172 (78) | 149 (81) | 59 (86) | 182 (65) | <.001 | |||||
| >1.3 | 79 (13) | 48 (22) | 36 (19) | 10 (14) | 99 (35) | ||||||
| Urea, mg/dL | 32 (4-255) | 547 (100) | 42 (1.9-162) | 205 (100) | 41 (12-195) | 170 (100) | 38 (12-117) | 68 (100) | 47 (10-267) | 246 (100) | <.001* |
| Uric acid, mg/dL | 4.7 (0-14.4) | 540 (100) | 5.6 (0-17.1) | 187 (100) | 5.7 (1.7-13.6) | 158 (100) | 5.3 (0.1-11) | 61 (100) | 6.1 (0.6-21) | 218 (100) | <.001* |
| Bilirubin, mg/dL | 0.6 (0.1-8.1) | 582 (100) | 0.7 (0.1-9.9) | 207 (100) | 0.7 (0.2-5.3) | 172 (100) | 0.7 (0.2-3.9) | 65 (100) | 0.7 (0.2-8.1) | 248 (100) | .01* |
| AST, U/L | 22 (5-213) | 565 (100) | 22 (8-154) | 204 (100) | 20 (7-88) | 163 (100) | 22 (11-99) | 56 (100) | 23 (7-141) | 238 (100) | .18* |
| ALT, U/L | 20 (3-498) | 577 (100) | 19 (2-233) | 206 (100) | 16 (3-91) | 170 (100) | 18 (4-623) | 59 (100) | 19 (3-168) | 247 (100) | .02* |
| AP, U/L | 76 (2-1252) | 533 (100) | 75 (18-812) | 186 (100) | 73 (19-894) | 159 (100) | 75 (42-416) | 55 (100) | 95 (23-3571) | 208 (100) | <.001* |
| Albumin, g/dL | 3.7 (2-5.8) | 508 (100) | 3.7 (2-5.2) | 187 (100) | 3.8 (2.7-5.9) | 143 (100) | 4.1 (2-5) | 61 (100) | 3.4 (1.7-7) | 197 (100) | <.001* |
| ≤3.5 | 212 (42) | 86 (46) | 53 (37) | 18 (30) | 107 (54) | .001 | |||||
| > 3.5 | 296 (58) | 101 (54) | 90 (63) | 43 (70) | 90 (46) | ||||||
| LDH, U/L | 471 (12-9540) | 602 (100) | 437 (57-12 460) | 253 (100) | 385 (61-4266) | 220 (100) | 390 (144-3557) | 63 (100) | 617 (102-13 420) | 302 (100) | <.001* |
| Cytogenetics | 876 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| Normal | 255 (29) | 93 (29) | 107 (33) | 29 (37) | 90 (17) | <.001 | |||||
| Abnormal | 422 (48) | 161 (50) | 152 (46) | 41 (52) | 192 (35) | ||||||
| No metaphases | 76 (9) | 27 (8) | 19 (6) | 2 (3) | 31 (6) | ||||||
| Not available | 123 (14) | 44 (14) | 50 (15) | 7 (9) | 231 (42) | ||||||
| MRC cytogenetic risk | 690 (100) | 256 (100) | 263 (100) | 71 (100) | 277 (100) | ||||||
| Favorable | 40 (6) | 8 (3) | 2 (1) | 0 (0) | 4 (2) | <.001 | |||||
| Intermediate | 386 (56) | 147 (57) | 150 (57) | 46 (65) | 148 (53) | ||||||
| Adverse | 264 (38) | 101 (40) | 111 (42) | 25 (35) | 125 (45) | ||||||
| FLT3-ITD | 467 (100) | 174 (100) | 118 (100) | 70 (100) | 122 (100) | ||||||
| Positive | 54 (12) | 20 (11) | 10 (8) | 10 (14) | 12 (10) | .76 | |||||
| Negative | 413 (88) | 154 (89) | 10108 (92) | 60 (85) | 110 (90) | ||||||
| NPM1 | 427 (100) | 169 (100) | 113 (100) | 67 (100) | 113 (100) | ||||||
| Positive | 85 (20) | 25 (15) | 16 (14) | 8 (12) | 11 (10) | .06 | |||||
| Negative | 342 (80) | 144 (85) | 97 (86) | 59 (88) | 102 (90) | ||||||
| Period | 876 (100) | 325 (100) | 328 (100) | 79 (100) | 544 (100) | ||||||
| 1990-1994 | 33 (4) | 7 (2) | 0 (0) | 0 (0) | 13 (2) | <.001 | |||||
| 1995-1999 | 68 (8) | 2 (1) | 0 (0) | 0 (0) | 28 (5) | ||||||
| 2000-2004 | 92 (11) | 2 (1) | 3 (1) | 0 (0) | 66 (12) | ||||||
| 2005-2009 | 168 (19) | 23 (7) | 51 (16) | 0 (0) | 164 (30) | ||||||
| 2010-2014 | 290 (33) | 171 (53) | 132 (40) | 23 (29) | 192 (35) | ||||||
| 2015-2019 | 225 (26) | 120 (37) | 142 (43) | 56 (71) | 81 (15) | ||||||
P compare continuous variables.